Related Experiment Videos
Carboxypeptidase G2 rescue after high-dose methotrexate
L M DeAngelis1, W P Tong, S Lin
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. deangell@mskcc.org
Summary
Carboxypeptidase G2 (CPG2) effectively rescues patients from high-dose methotrexate (HD-MTX) by rapidly lowering plasma levels. This pilot study found CPG2 safe and effective for recurrent cerebral lymphoma, offering an alternative to leucovorin rescue.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Recurrent primary CNS lymphoma (PCNSL) presents significant treatment challenges.
- High-dose methotrexate (HD-MTX) is a cornerstone therapy for PCNSL, but its use is limited by toxicity.
- Effective rescue strategies are crucial for tolerating HD-MTX.
Purpose of the Study:
- To pilot the safety and efficacy of carboxypeptidase G2 (CPG2) as a rescue agent after HD-MTX.
- To evaluate CPG2's impact on methotrexate (MTX) levels in plasma and cerebrospinal fluid (CSF).
- To assess the development of anti-CPG2 antibodies and overall toxicity.
Main Methods:
- A pilot study involving four patients with recurrent PCNSL.
- Administration of HD-MTX (3.0 g/m2) followed by CPG2 rescue (50 U/kg) at 12 and 18 hours.
- Serial blood and CSF sampling to measure MTX, CPG2, and DAMPA levels.
- Monitoring for anti-CPG2 antibodies and clinical toxicity for at least 2 weeks.
Main Results:
- CPG2 rapidly reduced plasma MTX levels by at least 2 logs within 5 minutes.
- The cleavage product DAMPA was detected as MTX levels decreased.
- CSF MTX levels remained elevated for 4 hours post-CPG2, declining predictably.
- No anti-CPG2 antibodies or significant MTX/CPG2 toxicity were observed.
Conclusions:
- CPG2 is a safe and effective rescue agent following HD-MTX.
- CPG2 offers a viable alternative to leucovorin rescue.
- CPG2's lack of effect on CSF MTX levels makes it potentially valuable for CNS tumors.